CONFERENCE DAY TWO

8:00 am Digital Networking Room Opens

8:25 am Chair’s Opening Remarks

Mobilizing Novel Drugs Against the Hippo Pathway to Achieve Effective & Sustained Inhibition of TEAD

8:30 am Developing Effective Covalent Inhibitors Against TEAD as Candidates for Cancer Therapy

  • Wanjin Hong Chief Business Development Officer, Biomedical Research Council (BMRC) at A*STAR

9:00 am Revealing Pre-Clinical Findings for TYK 1054 to Target the Hippo/TEAD Pathway

  • Shengli Dong Executive Director for Biology, TYK Medicines

9:45 am Advancing a pan-TEAD PPI Inhibitor of the YAP/TEAD Complex to Tackle Mesothelioma Through Protein Liquid-Liquid Phase Separation

  • Jidong Zhu Chief executive officer and Co-Founder, Etern bioPharma

10:15 am Morning Break & Virtual Networking

Predicting Clinical Patient Sensitivity for Hippo-Targeted Drugs Using Fit-For-Purpose Pre- Clinical Models to Improve Patient Selection

10:45 am Preclinical Approaches for Predicting Sensitivity to YAP/TAZ-TEAD Inhibition in Cancer

  • John Lamar Assistant Professor, Albany Medical Center

11:15 am Panel Discussion: How Can We Use Pre-Clinical Models to Accelerate the Translation of Hippo-Targeted Drugs Towards the Clinic?

  • Zhi Liang Chu Founder, Chief Executive Officer & Chief scientific officer, Crossignal Therapeutics
  • John Lamar Assistant Professor, Albany Medical Center
  • Satu Juhila Project Leader, Orion Pharma
  • Carsten Hansen Reader, Institute for Regeneration & Repair, University of Edinburgh

12:00 pm Pre-Clinical Mesothelioma Platform to Evaluate Hippo Pathway Targeting Compounds

  • Carsten Hansen Reader, Institute for Regeneration & Repair, University of Edinburgh

12:30 pm Lunch Break & Virtual Networking

Tackling Late-Stage Preclinical & Early Clinical Challenges to Expedite TEAD Inhibitors to the Clinic

Chair: Melanie Frigault, Consultant, Translational Medicine, Vincerx Pharma

1:30 pm Journey of VT3989: Clinical Insights & Overcoming Challenges

2:00 pm Roundtable Discussion: Translating TEAD Inhibitors to the Clinic: Anticipating & Overcoming Bottlenecks During Late-Preclinical & Early Clinical Stages

2:30 pm Afternoon Break & Virtual Networking

Leveraging Mechanistic Insights to Realize the Potential of Novel Targets in the Hippo Pathway for Therapeutic Interventions

3:00 pm Leveraging Mechano-Biology to Utilize the Hippo Pathway in the Fight Against Fibrotic Diseases & Desmoplastic Tumors

3:30 pm Discovery of Therapeutic Vulnerability in Epithelioid Hemangioendothelioma: a TAZ-CAMTA1 Driven Cancer

4:00 pm Using Proteomics & Genomics to Investigate the TEAD Protein Interaction Networks in Cancer

4:30 pm Chair’s Closing Remarks

4:40 pm End of the 3rd Hippo Pathway Targeted Drug Development Summit